Fixed drug eruption induced by trimethoprim-sulfamethoxazole: Evidence for a link to HLA-A30 B13 Cw6 haplotype
Background: Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found between B22 antigen and feprazone-induced FDE. Objective: Our aim was to investigate the association between HLA class I antigens and FDE in Turke...
Saved in:
Published in: | Journal of the American Academy of Dermatology Vol. 45; no. 5; pp. 712 - 717 |
---|---|
Main Authors: | , |
Format: | Journal Article Conference Proceeding |
Language: | English |
Published: |
New York, NY
Elsevier Inc
01-11-2001
Elsevier |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Background: Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found between B22 antigen and feprazone-induced FDE. Objective: Our aim was to investigate the association between HLA class I antigens and FDE in Turkey, a country where feprazone is not on the market and trimethoprim-sulfamethoxazole is most often the offending drug. Methods: HLA class I typing was performed by lymphocytotoxicity assay in 67 unrelated patients with FDE, all established by oral provocation. The frequencies are compared with those of 2378 control subjects. Results: Significantly higher (P < .001) frequencies of the A30 antigen and A30 B13 Cw6 haplotype were found in 42 patients with FDE induced by trimethoprim-sulfamethoxazole. HLA-B55 (split of B22) was present exclusively in trimethoprim-sulfamethoxazole-induced FDE, and in higher frequency than in control subjects. Conclusion: To our knowledge, ours is the first report indicating a link between A30 B13 Cw6 haplotype and trimethoprim-sulfamethoxazole-induced FDE. In addition, HLA-B22 was increased in patients with FDE caused by a drug other than feprazone. (J Am Acad Dermatol 2001;45:712-7.) |
---|---|
AbstractList | Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found between B22 antigen and feprazone-induced FDE.
Our aim was to investigate the association between HLA class I antigens and FDE in Turkey, a country where feprazone is not on the market and trimethoprim-sulfamethoxazole is most often the offending drug.
HLA class I typing was performed by lymphocytotoxicity assay in 67 unrelated patients with FDE, all established by oral provocation. The frequencies are compared with those of 2378 control subjects.
Significantly higher (P <.001) frequencies of the A30 antigen and A30 B13 Cw6 haplotype were found in 42 patients with FDE induced by trimethoprim-sulfamethoxazole. HLA-B55 (split of B22) was present exclusively in trimethoprim-sulfamethoxazole-induced FDE, and in higher frequency than in control subjects.
To our knowledge, ours is the first report indicating a link between A30 B13 Cw6 haplotype and trimethoprim-sulfamethoxazole-induced FDE. In addition, HLA-B22 was increased in patients with FDE caused by a drug other than feprazone. Background: Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found between B22 antigen and feprazone-induced FDE. Objective: Our aim was to investigate the association between HLA class I antigens and FDE in Turkey, a country where feprazone is not on the market and trimethoprim-sulfamethoxazole is most often the offending drug. Methods: HLA class I typing was performed by lymphocytotoxicity assay in 67 unrelated patients with FDE, all established by oral provocation. The frequencies are compared with those of 2378 control subjects. Results: Significantly higher (P < .001) frequencies of the A30 antigen and A30 B13 Cw6 haplotype were found in 42 patients with FDE induced by trimethoprim-sulfamethoxazole. HLA-B55 (split of B22) was present exclusively in trimethoprim-sulfamethoxazole-induced FDE, and in higher frequency than in control subjects. Conclusion: To our knowledge, ours is the first report indicating a link between A30 B13 Cw6 haplotype and trimethoprim-sulfamethoxazole-induced FDE. In addition, HLA-B22 was increased in patients with FDE caused by a drug other than feprazone. (J Am Acad Dermatol 2001;45:712-7.) |
Author | Akar, Uğur Özkaya-Bayazit, Esen |
Author_xml | – sequence: 1 givenname: Esen surname: Özkaya-Bayazit fullname: Özkaya-Bayazit, Esen – sequence: 2 givenname: Uğur surname: Akar fullname: Akar, Uğur |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14108073$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11606921$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kEFv2zAMRoWixZJmO-826LKjU9JyJWu3LEjaAgF66c6GItGtOscyJDtr9uvnLAF66okg8Ujwe9fssg0tMfYVYY4g1c3u1c1zAJwjqvK2uGBTBK0yqUp1yaaAGjIt83zCrlN6BQBdCPWJTRAlSJ3jlLVr_0aOuzg8c4pD1_vQct-6wY7T7YH30e-ofwndWLM0NLX5376Zv6GhH3y1945aS7wOkRve-PY37wO_3yyyhQD-EwVf_pH8xXRN6A8dfWZXtWkSfTnXGfu1Xj0t77PN493DcrHJrFCizyTWikStndRGl0UupVU1amPI2dIV2pYgC21wHBGK4pZKk5cOcgFaSqmVmLGb010bQ0qR6uoYwMRDhVAdzVWjueporjqZGze-nTa6Ybsj986fVY3A9zNgkjVNHU1rfXrnCoQSlBg5feJozLf3FKtk_dGR85FsX7ngP3ziH_3jio4 |
CODEN | JAADDB |
CitedBy_id | crossref_primary_10_1002_0471142905_hg0919s60 crossref_primary_10_1002_0471141755_ph0610s21 crossref_primary_10_1592_phco_24_9_856_36106 crossref_primary_10_1007_s12016_014_8418_y crossref_primary_10_1016_j_tripleo_2008_05_004 crossref_primary_10_1002_14651858_CD010891 crossref_primary_10_1016_j_jaad_2012_08_019 crossref_primary_10_1111_j_1610_0387_2007_06491_x crossref_primary_10_1016_j_humimm_2006_10_015 crossref_primary_10_1016_j_therap_2023_09_011 crossref_primary_10_2217_pgs_12_108 crossref_primary_10_2217_pme_10_46 crossref_primary_10_1002_0471141755_ph0610s36 crossref_primary_10_1016_j_jaip_2013_11_005 crossref_primary_10_1124_jpet_103_050112 crossref_primary_10_1016_S0140_6736_02_07899_6 crossref_primary_10_1016_j_arth_2023_09_004 crossref_primary_10_3390_ph4010069 crossref_primary_10_2217_pgs_09_6 crossref_primary_10_1016_j_jaci_2020_08_003 crossref_primary_10_1016_j_pharmthera_2019_01_002 crossref_primary_10_3390_medicina57090925 crossref_primary_10_1097_00002030_200501280_00011 crossref_primary_10_1097_00130832_200208000_00004 crossref_primary_10_1371_journal_pone_0156000 crossref_primary_10_1002_0471142905_hg0919s49 crossref_primary_10_1186_1755_8794_5_32 crossref_primary_10_3389_fgene_2021_641905 crossref_primary_10_2165_00128415_200208850_00011 crossref_primary_10_1097_QCO_0000000000000323 crossref_primary_10_1111_j_1939_1676_2012_00965_x crossref_primary_10_1586_edm_09_1 crossref_primary_10_1016_j_coi_2012_10_002 crossref_primary_10_1016_j_piel_2010_11_015 crossref_primary_10_2147_DHPS_S347522 crossref_primary_10_4103_cdr_cdr_79_22 crossref_primary_10_1097_01_aids_0000238408_82947_09 crossref_primary_10_2217_pgs_10_77 crossref_primary_10_36691_RJA335 crossref_primary_10_1111_ddg_14870 crossref_primary_10_1053_j_seminoncol_2005_11_004 crossref_primary_10_1111_j_1365_2885_2004_00576_x crossref_primary_10_1051_medsci_2002184389 crossref_primary_10_1002_14651858_CD010891_pub2 crossref_primary_10_7759_cureus_18599 crossref_primary_10_1016_j_jaip_2022_02_004 crossref_primary_10_1021_acsomega_0c06066 crossref_primary_10_1146_annurev_pharmtox_010611_134701 crossref_primary_10_1002_hep_31258 crossref_primary_10_1177_120347540400800104 crossref_primary_10_1007_s00112_019_00810_0 crossref_primary_10_1111_ddg_14870_g |
ContentType | Journal Article Conference Proceeding |
Copyright | 2001 The American Academy of Dermatology, Inc. 2002 INIST-CNRS |
Copyright_xml | – notice: 2001 The American Academy of Dermatology, Inc. – notice: 2002 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1067/mjd.2001.117854 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6787 |
EndPage | 717 |
ExternalDocumentID | 10_1067_mjd_2001_117854 11606921 14108073 S019096220164146X |
Genre | Journal Article |
GroupedDBID | --- --K --M -RU .1- .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8F7 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFNM ABFRF ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HX~ HZ~ IHE J1W J5H KOM LCYCR LZ2 M27 M41 MO0 N9A O-L O9- OAUVE OB. OBH OHH OM~ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SDF SDG SDP SEL SES SJN SPCBC SSH SSZ T5K TEORI UHS UNMZH UV1 WOW WUQ Y6R YFH Z5R ZCG ZGI ZY1 ~G- 08R ABPIF IQODW AAXKI ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c373t-61f7e3f9d69a984266c7f19aaedc8d49c80649a119ae1345e8a28d02309666973 |
ISSN | 0190-9622 |
IngestDate | Thu Sep 26 18:46:14 EDT 2024 Sat Sep 28 07:40:04 EDT 2024 Sun Oct 22 16:05:22 EDT 2023 Fri Feb 23 02:27:49 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human Sulfanilamide derivatives HLA-System Skin disease Drug combination Sulfonamide Toxicity Fixed drug eruption Trimethoprim Sulfamethoxazole Antiinfectious Skin Haplotype |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MeetingName | Isotretinoin. A state-of-the-art conference |
MergedId | FETCHMERGED-LOGICAL-c373t-61f7e3f9d69a984266c7f19aaedc8d49c80649a119ae1345e8a28d02309666973 |
PMID | 11606921 |
PageCount | 6 |
ParticipantIDs | crossref_primary_10_1067_mjd_2001_117854 pubmed_primary_11606921 pascalfrancis_primary_14108073 elsevier_sciencedirect_doi_10_1067_mjd_2001_117854 |
PublicationCentury | 2000 |
PublicationDate | 2001-11-01 |
PublicationDateYYYYMMDD | 2001-11-01 |
PublicationDate_xml | – month: 11 year: 2001 text: 2001-11-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Journal of the American Academy of Dermatology |
PublicationTitleAlternate | J Am Acad Dermatol |
PublicationYear | 2001 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
SSID | ssj0009437 |
Score | 1.9591157 |
Snippet | Background: Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found... Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found between B22... |
SourceID | crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 712 |
SubjectTerms | Adolescent Adult Aged Anti-Infective Agents - adverse effects Anti-Infective Agents - immunology Biological and medical sciences Child Child, Preschool Drug Eruptions - immunology Drug toxicity and drugs side effects treatment Female Haplotypes Histocompatibility Testing HLA-A Antigens - analysis HLA-A Antigens - biosynthesis Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Toxicity: skin, dermoskeleton Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects Trimethoprim, Sulfamethoxazole Drug Combination - immunology |
Title | Fixed drug eruption induced by trimethoprim-sulfamethoxazole: Evidence for a link to HLA-A30 B13 Cw6 haplotype |
URI | https://dx.doi.org/10.1067/mjd.2001.117854 https://www.ncbi.nlm.nih.gov/pubmed/11606921 |
Volume | 45 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6TkJIPPAxWDeY_MADUmRI4jSOecu2oo4BQqKTxl4iL3Y20GiiNhGDv56z43y0bCAeeHEbV2na3C935_Pd7xB6PvZUyLPMJb6gigSAIcJp4JI08KU0hNuGnX_6iX04jQ4nwWQwaBqTdHP_VdIwB7LWlbP_IO32S2EC3oPMYQSpw_i73G80Pz0fs1c3Mrep8GZH_VDr47IXUbetjL5cg_8pF9WFoxZVYfMgZZVaN1W3Aigv8wJeybK6yoQ5vBY_dYqiji00PUrr3ExH7w5r53b6LiYxdZ19jzoH30PnUhRXuQ7-tiHes-P4c0z2YTg7mhn9vOxq1OLj2KRrnFxUi5UohWfL9drQmbXz_UgmB1iEdVHyS1VrX5czAtaT9dVzzTZpYTju6Vpm86-VPWI3WgSwxiCyb18NK6yn96ijmrV6lXt7zSa2mYo6DTYCNbiBNk0T-SHajI8mp287YueAtiX5-u809FEhe7V20ds8n3uFWMLzmNWNVNaWN8bNmd1HW10BKP7YYusBGqj5Q3Tnvc3DeIRygxSskYIbpGCLFHz-A_8RKfg1bnCCASdYYI0TXObY4gQDTjDgBLc42UInbyazgymxrTtIShktSehlTNGMy5ALHmkvMGWZx4VQMo1kwNMIXGEuPJhSHg3GKhJ-JPV6GJbfIWf0MRrO87naRlieU5r5qQS_XW_ic6659VMeCJZq8kA1Qi-a25oUNUNLYjIrQpaABHSfVS-pJTBCfnPbE-tg1o5jAmi5_aS9FQF1F7HQGKEntcS6T7zQDeF37vzt1F10t3tYnqJhuajUM7SxlNWexdkvJsej4g |
link.rule.ids | 310,311,315,782,786,791,792,23939,23940,25149,27933,27934 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=Journal+of+the+American+Academy+of+Dermatology&rft.atitle=Fixed+drug+eruption+induced+by+trimethoprim-sulfamethoxazole+%3A+Evidence+for+a+link+to+HLA-A30+B13+Cw6+haplotype&rft.au=OZKAYA-BAYAZIT%2C+Esen&rft.au=AKAR%2C+Ugur&rft.date=2001-11-01&rft.pub=Elsevier&rft.issn=0190-9622&rft.eissn=1097-6787&rft.volume=45&rft.issue=5&rft.spage=712&rft.epage=717&rft_id=info:doi/10.1067%2Fmjd.2001.117854&rft.externalDBID=n%2Fa&rft.externalDocID=14108073 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0190-9622&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0190-9622&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0190-9622&client=summon |